Lam Research Corp (NASDAQ:LRCX) reported strong financial results for the fourth quarter of 2024, surpassing analysts' ...
Earnings per ... EPS figure might nonetheless lead to a price increase if analysts were expecting an even worse result. It is important to always judge EPS in relation to the company’s share ...
Stock analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a research note issued on Thursday, January 23rd. HC Wainwright analyst P.